Tuesday, September 11, 2007

ImClone, Repligen settle; Repligen stock goes down

In another chapter in the ImClone/Erbitux saga, Reuters reported on Sept. 10: ImClone Systems Inc said on Monday [Sept. 10] it will pay Repligen Corp $65 million to settle a patent infringement lawsuit related to ImClone's cancer drug Erbitux (...) The agreement was better for ImClone than expected, and worse for Repligen, sending Repligen's shares down nearly 16 percent.


Post a Comment

<< Home